Results for quarter ended 30th June 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Parmax Pharma reported a sharp deterioration in Q1 FY26 results, with revenue from operations falling to Rs 1.94 crore from Rs 7.82 crore in the same quarter last year — a drop of roughly 75% year-on-year. The company swung from a small profit of Rs 1.23 lakh in Q1 FY25 to a net loss of Rs 76.45 lakh in Q1 FY26, translating to a loss per share of Rs 2.04 versus an EPS of Rs 0.03 a year ago. Total expenses at Rs 2.71 crore exceeded total income of Rs 1.95 crore, driving the operating loss. For the full year FY25, the company had already reported a net loss of Rs 2.09 crore, partly impacted by exceptional items of Rs 1.07 crore. Separately, the board appointed Mr. Samsad Alam Khan as Secretarial Auditor for a five-year term from FY26 to FY30, subject to shareholder approval.
The steep revenue decline and return to losses signal serious business stress for shareholders, raising concerns about the company's operational viability and future growth prospects. The stock may face negative sentiment given the weak quarterly performance.